MAPT and Parkinson disease: GSK3 and O-GlcNAc are known to impact neurological disorders such as Alzheimer's and Parkinson's diseases through co-regulation of β-catenin, tau, and α-synuclein (Hur and Zhou, 2010; Yuzwa and Vocadlo, 2014; Wheatley et al., 2019; Lauretti et al., 2020; Muha et al., 2020).